Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2021-03-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于对公司2021年度日常关联交易事项的事前认可意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors regarding prior approval of routine related-party transactions for the fiscal year 2021. It references regulatory guidelines and company rules but does not contain financial statements or detailed financial data. The document is short (439 characters) and serves as an official opinion or announcement rather than a full report. It is not an annual report, audit report, or financial statement. It is also not a voting result or management change announcement. The content fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure about governance and related-party transactions without substantive financial data.
2021-03-11 Chinese
2020年年度报告
Annual Report Classification · 100% confidence The document is titled "普洛药业股份有限公司 2020 年年度报告全文" which translates to "Apeloa Pharmaceutical Co., Ltd. 2020 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data for the year 2020, business summary, management discussion and analysis, financial statements, and other comprehensive disclosures. The document length is 15,000 characters, indicating a full report rather than a brief announcement. It includes audited financial data, management statements, and detailed operational and financial analysis for the fiscal year 2020. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2020
2021-03-11 Chinese
独立董事述职报告（陈凌）
Board/Management Information Classification · 95% confidence The document is titled '2020 年度独立董事述职报告' which translates to '2020 Annual Independent Director's Work Report'. It details the independent director's attendance, opinions, committee work, and efforts to protect investor rights during the year 2020. The content focuses on the director's duties and activities rather than financial results or audit opinions. It is a report by an independent director about their role and responsibilities, which fits the category of Board/Management Information (MANG) as it relates to board members' activities and governance roles. The document length is 1611 characters, indicating it is a full report rather than a brief announcement. Therefore, the classification is MANG with high confidence.
2021-03-11 Chinese
独立董事述职报告（张爱珠）
Board/Management Information Classification · 95% confidence The document is titled '2020 年度独立董事述职报告' which translates to '2020 Annual Independent Director's Work Report'. It details the independent director's attendance at board meetings, opinions on various company matters, committee work, and efforts to protect investor rights during the 2020 fiscal year. The content is a narrative report on the director's duties and activities rather than a financial report or regulatory filing. It does not contain financial statements or audit results, nor is it an announcement or certification. This type of document is best classified under Board/Management Information (MANG) as it relates to the activities and reports of a board member.
2021-03-11 Chinese
普洛药业股份有限公司未来三年（2021年—2023年）股东回报规划
Notice of Dividend Amount Classification · 90% confidence The document is titled as a "Future Three-Year (2021-2023) Shareholder Return Plan" issued by the board of directors of 普洛药业股份有限公司. It outlines the company's dividend policy, principles for profit distribution, and mechanisms for decision-making and adjustments related to shareholder returns over the next three years. The content focuses on dividend distribution strategy, cash dividend priorities, and shareholder communication, rather than reporting actual financial results or earnings. The document is a policy or planning announcement related to dividends and shareholder returns, not a formal dividend amount notice or an earnings release. It is also not a full annual or interim report, nor a regulatory filing or proxy solicitation. Given the nature of the document as a forward-looking shareholder return plan, it best fits the category of Notice of Dividend Amount (DIV), which includes announcements about dividend policies and plans for shareholder returns.
2021-03-11 Chinese
2020年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the "2020年度财务决算报告" which translates to "2020 Annual Financial Settlement Report." It contains detailed financial data for the full year 2020, including total assets, liabilities, equity, revenue, profit, and cash flow statements. The report is audited by an accounting firm, indicating it is a formal financial report. The content includes comprehensive financial performance and position data for the entire fiscal year, which aligns with the characteristics of an Annual Report (10-K). The document length is 2236 characters, which is relatively short but contains substantive financial data rather than just an announcement or certification. Therefore, it is classified as an Annual Report (10-K). FY 2020
2021-03-11 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.